Xilio Therapeutics, Inc.XLO
Price (close)
$9.00
Market cap
$59.2M
P/E
—
Revenue (TTM)
$64.1M
Net income
-$21.8M
Dividend yield
—
1-year total return
-15.3%
Net margin
-34.1%
Revenue growth
327.3%
Debt / equity
—
What Xilio Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $6.3M | $43.8M |
| Net income | -$55.2M | -$75.8M | -$88.2M | -$76.4M | -$58.2M | -$35.0M |
| Free cash flow | -$38.3M | -$81.9M | -$77.6M | -$69.1M | -$18.4M | -$5.5M |
More on XLO.
- Xilio Therapeutics, Inc. summary
- Xilio Therapeutics, Inc. financial statements
- Xilio Therapeutics, Inc. key metrics
- Xilio Therapeutics, Inc. health scores and style box
- Xilio Therapeutics, Inc. earnings
- Xilio Therapeutics, Inc. dividends
- Xilio Therapeutics, Inc. valuation
- Xilio Therapeutics, Inc. ownership and insiders
- Xilio Therapeutics, Inc. peers
Figures from Xilio Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.